From: Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis
System organ class allocation | Total (838 PYs) | Elderly patients (212 PYs) | Younger patients (626 PYs) | IRR (elderly patient/younger patients) |
---|---|---|---|---|
Total | 5.37 (3.92 – 7.19) | 6.13 (3.27 – 10.49) | 5.11 (3.50 – 7.22) | 1.20 (0.63–2.29) |
 General disorders | 0.12 (0.00 – 0.66) | 0.47 (0.01 – 2.63) | – |  |
 Hypersensitivity | 0.24 (0.03 – 0.86) | – | 0.32 (0.04 – 1.15) |  |
 Hepatobiliary disorders | 0.48 (0.13 – 1.22) | 0.47 (0.01 – 2.63) | 0.48 (0.10 – 1.40) | 0.98 (0.10–9.46) |
 Infections | 2.39 (1.46 – 3.69) | 2.36 (0.77 – 5.50) | 2.40 (1.34 – 3.95) | 0.98 (0.36–2.71) |
 Injury | 0.60 (0.19 – 1.39) | 0.94 (0.11 – 3.41) | 0.48 (0.10 – 1.40) | 1.97 (0.33–11.78) |
 Musculoskeletal and connective tissue disorders | 0.24 (0.03 – 0.86) | – | 0.32 (0.04 – 1.15) |  |
 Malignant | 0.95 (0.41 – 1.88) | 0.94 (0.11 – 3.41) | 0.96 (0.35 – 2.09) | 0.98 (0.20–4.88) |
 Nervous system disorders | 0.12 (0.00 – 0.66) | 0.47 (0.01 – 2.36) | – |  |
 Respiratory, thoracic, and mediastinal disorders | 0.24 (0.03 – 0.86) | 0.47 (0.01 – 2.36) | 0.16 (0.00 – 0.89) | 2.95 (0.18–47.21) |